News
Duchenne muscular dystrophy families are sharing stories about Elevidys complications on social media. But they aren’t ...
17h
MarketBeat on MSNSarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesIn another tragic incident, Sarepta Therapeutics (NASDAQ: SRPT) saw a second death in connection with its Duchenne muscular ...
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research ...
Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...
In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...
I am upgrading Dyne Therapeutics stock to a 'Buy' rating due to promising late-stage DM1 and DMD drug candidates and ...
CSL Behring’s Andembry is now approved as a subcutaneous, self-injection for hereditary angioedema (HAE) patients ages 12 and older and will be available by the end of June 2025.
The average cost of a home in the capital rose 2.6% during the month from £552,402 to £566,614 according to the Land Registry ...
Meta Platforms’ latest move to monetize WhatsApp could add billions to its revenue over time, according to a new note from Morgan Stanley (NYSE:MS).
President Javier Milei's severe budget cuts to Argentina's public health system have led to a decline in care, particularly affecting cancer patients, according to experts, government workers and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results